Ngenla (somatrogon-ghla) is a once-weekly recombinant human growth hormone analog used to treat pediatric patients with growth hormone deficiency (pGHD). By extending the hormone’s half-life, Ngenla offers the convenience of weekly dosing compared to traditional daily injections, improving treatment adherence and quality of life for children and families.

Ngenla® (somatrogon-ghla) is a long-acting, recombinant human growth hormone analog designed to treat pediatric patients with growth hormone deficiency (pGHD). Developed for once-weekly subcutaneous administration, Ngenla® provides an innovative alternative to daily growth hormone therapies, helping to simplify treatment routines and support better adherence.

Medikinet XL 10mg is a pharmaceutical product specifically designed for the treatment of attention-deficit hyperactivity disorder (ADHD) in children aged six years and above, as well as in adolescents. This modified-release formulation provides a dual-phase release of the active ingredient, methylphenidate hydrochloride, enabling both immediate and sustained effects to optimize symptom control throughout the day.

Disease Indications: Leukemia, Bile Duct Cancer

Manufacturer: Agios Pharmaceuticals, Inc.

Usage: Oral

Medicine approved by:

Food and Drug Administration (FDA)

Tibsovo (ivosidenib) is designed to treat two conditions: relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation, and previously treated, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with the same mutation.

Disease Indications: Breast Cancer

Manufacturer: Novartis

Usage: Oral

Medicine approved by:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Piqray (alpelisib) is prescribed alongside fulvestrant to treat advanced or metastatic breast cancer in postmenopausal women and men. This combination therapy targets hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with PIK3CA mutation, identified by an FDA-approved test, after progression on prior endocrine-based treatment.

Disease Indications: Wilson’s disease

Manufacturer: GMP-Orphan (GMPO)

Usage: Intravenous

Medicine approved by:

European Medical Agency (EMA)

Cuprior, manufactured by GMP-Orphan (GMPO), is a vital intravenous medication used to treat Wilson’s disease, a genetic disorder causing excessive copper accumulation in the body.

Disease Indications: Multiple Sclerosis

Manufacturer: Biogen

Usage: Oral

Medicine approved by:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Health Canada

Therapeutic Goods Administration (TGA)

Medsafe (NZ)

Tecfidera, containing Dimethyl Fumarate, is an oral medication used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It helps reduce the frequency of relapses and delays the progression of disability.

Disease Indications: Amyotrophic Lateral Sclerosis (ALS)

Manufacturer: Bruschettini s.r.l.

Usage: Oral

Medicine approved by:

Italian Medicines Agency (AIFA)

Tudcabil contains Tauroursodeoxycholic Acid (TUDCA), known for its potential neuroprotective properties. It is indicated for patients with Amyotrophic Lateral Sclerosis (ALS) and may help slow disease progression and improve quality of life.